Zacks: ESSA Pharma Inc. (EPIX) Receives Consensus Recommendation of “Strong Buy” from Brokerages
Shares of ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI) have been given a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy recommendation.
Analysts have set a twelve-month consensus target price of $5.10 for the company and are forecasting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also assigned ESSA Pharma an industry rank of 104 out of 265 based on the ratings given to related companies.
A number of research analysts have issued reports on the stock. Dawson James restated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. Bloom Burton restated a “buy” rating on shares of ESSA Pharma in a research report on Thursday, May 18th. ValuEngine downgraded shares of ESSA Pharma from a “sell” rating to a “strong sell” rating in a research report on Wednesday, June 7th. Finally, Zacks Investment Research downgraded shares of ESSA Pharma from a “hold” rating to a “sell” rating in a research report on Thursday, May 18th.
ESSA Pharma (NASDAQ EPIX) traded up 37.50% on Thursday, hitting $0.44. 1,628,998 shares of the stock traded hands. The stock has a 50-day moving average of $0.34 and a 200-day moving average of $1.44. The firm’s market cap is $12.80 million. ESSA Pharma has a 12-month low of $0.25 and a 12-month high of $3.59.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.